PROphetNSCLC™
OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to provide physicians with crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient
PROphet® combines bioinformatics, system biology, proteomic pattern recognition, and machine learning to predict a patient's probability of clinical benefit (Progression-Free Survival>12 months) and overall survival, addressing a major industry challenge: PD-1/PD-L1 inhibitors as a single agent or in combination with chemotherapy?
...
More Info Less Info